Assessing unused residual Pfizer-BioNTech COVID-19 vaccine: a community observational study
Stephen Hubbard, Rajlaxmi Bais
doi: https://doi.org/10.1101/2021.08.03.21261569
Stephen Hubbard
Bainbridge Prepares, Bainbridge Island, WA
MD, FACCRajlaxmi Bais
Bainbridge Prepares, Bainbridge Island, WA
DNP, ARNPData Availability
All data used in the study are available for review.
Posted August 09, 2021.
Assessing unused residual Pfizer-BioNTech COVID-19 vaccine: a community observational study
Stephen Hubbard, Rajlaxmi Bais
medRxiv 2021.08.03.21261569; doi: https://doi.org/10.1101/2021.08.03.21261569
Subject Area
Subject Areas
- Addiction Medicine (386)
- Allergy and Immunology (701)
- Anesthesia (193)
- Cardiovascular Medicine (2859)
- Dermatology (244)
- Emergency Medicine (431)
- Epidemiology (12569)
- Forensic Medicine (10)
- Gastroenterology (807)
- Genetic and Genomic Medicine (4447)
- Geriatric Medicine (402)
- Health Economics (716)
- Health Informatics (2856)
- Health Policy (1050)
- Hematology (376)
- HIV/AIDS (893)
- Medical Education (415)
- Medical Ethics (114)
- Nephrology (464)
- Neurology (4201)
- Nursing (223)
- Nutrition (617)
- Oncology (2205)
- Ophthalmology (626)
- Orthopedics (254)
- Otolaryngology (319)
- Pain Medicine (269)
- Palliative Medicine (83)
- Pathology (488)
- Pediatrics (1172)
- Primary Care Research (483)
- Public and Global Health (6787)
- Radiology and Imaging (1494)
- Respiratory Medicine (902)
- Rheumatology (430)
- Sports Medicine (369)
- Surgery (473)
- Toxicology (57)
- Transplantation (202)
- Urology (174)